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ABSTRACT
Objectives: Lithium is a mainstay of bipolar disorder
treatment, however, there are still differences in opinion
on the effects of lithium use on renal function. The aim of
this analysis was to determine if there is an association
between short-term exposure to various elevated lithium
levels and estimated-glomerular filtration rate (eGFR) at
≤3 months, 6 months (±3 months) and 1 year
(±3 months) follow-up.
Setting: Norfolk-wide (UK) lithium register and
database.
Participants: 699 patients from the Norfolk database.
Primary outcome measures: eGFR change from
baseline at ≤3 months, 6 months (±3 months) and
1 year (±3 months) after exposure to a lithium level
within these ranges: 0.81–1.0 mmol/L (group 2), 1.01–
1.2 mmol/L (group 3) and 1.21–2.0 mmol/L (group 4).
The reference group was patients whose lithium levels
never exceeded 0.8 mmol/L.
Results: Compared to the reference group, groups 3
and 4 showed a significant decrease in eGFR in the first
3 months after exposure (p=0.047 and p=0.040). At
6 months (±3 months) postexposure group 4 still
showed a decline in eGFR, however, this result was not
significant (p=0.298).
Conclusions: These results show for the first time that a
single incident of a lithium level >1.0 mmol/L is
associated with a significant decrease in eGFR in the
following 3 months when compared to patients whose
lithium levels never exceeded 0.8 mmol/L. It is still not
known whether the kidneys can recover this lost function
and the impact that more than a single exposure to a
level within these ranges can have on renal function.
These results suggest that lithium level monitoring
should be undertaken at least every 3 months, in line
with current UK guidelines and not be reduced further
until the impact of more than one exposure to these
lithium levels has been fully established.
INTRODUCTION
Lithium is a mainstay of bipolar disorder treat-
ment showing effectiveness in manic and
depressed phases of the illness.1 2 However,
despite its effectiveness there are some disad-
vantages to its use including its narrow thera-
peutic range and adverse effects on the
endocrine system. Several of these adverse
effects are related to the plasma levels of
lithium and as such it requires monitoring.
Lithium is primarily renally excreted, and a
declining glomerular ﬁltration rate will
increase the risk of lithium toxicity due to sys-
temic accumulation. This is of particular
concern in an ageing population where there
is postulated age-related decline in renal func-
tion.3 The range of levels suggested for a safe
and effective therapeutic target for lithium
within the UK has changed since the initial dis-
covery of its narrow therapeutic range and
now lies between 0.4 and 1.0 mmol/L.1 Levels
above 0.8 mmol/L have not only been asso-
ciated with a limited increase in efﬁcacy, but
have also been linked to higher risks of renal
toxicity, unwanted side effects and ﬂuctuations
of lithium level.4
From a recent systematic review and
meta-analysis, there is a small amount of evi-
dence that supports the theory that lithium
is associated with an increased risk of
Strengths and limitations of this study
▪ A large cohort of real-world patients was ana-
lysed, which is representative of other lithium-
taking populations studied.
▪ The lithium level ranges studied represent current
practice and consensus agreement within the UK.
▪ Diabetes mellitus, hypertension and cardiac
disease are prominent risk factors for renal glom-
erular function in the general as well as lithium-
treated populations. However, this data was not
reliably available from the database and could
therefore not be included in the analysis.
▪ The duration of lithium treatment before the ana-
lysis is not known; it was only known that the
patients had been on lithium for at least 1 year
prior to the analysis.
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progressive tubular damage. However, good quality evi-
dence on the long-term effects of lithium use on glom-
erular renal function is lacking.5–7 A meta-analysis of
case–control studies, conducted by McKnight et al,
demonstrated a reduction in urinary concentrating
ability of 15% in lithium-treated patients compared to
controls, with a mean observation time of 1 year. A small
decline in glomerular ﬁltration rate was also observed
(0–5 mL/min). The quality and quantity of the primary
evidence available was the main limitation of this study
with high-quality data from long-term randomised or
controlled cohort studies scarce, and all included obser-
vational studies had relatively small sample sizes from 10
to 346 patients.5
Owing to the narrow therapeutic range of lithium and
its effects on the endocrine system, UK national guid-
ance recommends that lithium levels are monitored at
least every 3 months and renal and thyroid function is
monitored every 6 months.1 A county-wide lithium data-
base and register (System TDM) was implemented in
Norfolk, UK in May 2002. Following the introduction of
the database the rates of lithium testing and monitoring
have improved, helping the county to achieve national
standards for the past 10 years with no known cases of
toxicity due to inadequate monitoring.8 Owing to the
size of the cohort of patients on the database it is hoped
that this analysis, as part of ongoing research, will estab-
lish the quantitative effect of different lithium levels on
glomerular renal function expanding on work carried
out by Rej et al,9 Aiff et al10 and Bendz et al.11
Aim and objective
The aim and objective of this analysis was to establish the
effects on eGFR at ≤3 months, 6 months (±3 months)
and 1 year (±3 months) follow-up post exposure to a
single lithium level within speciﬁed ranges, when patients
are monitored in line with current UK recommendations
for three monthly lithium level tests.
METHODS
The Norfolk county wide database (System TDM) has
over 10 years’ worth of data collected during routine
clinical practice allowing a retrospective cohort study to
be performed with a relatively large sample size.
Data extraction
Local research governance approval was received in
order to use the database, and for this speciﬁc project.
Data was then extracted from the database and analysed
to determine the effect of short-term exposures to differ-
ent lithium level ranges on eGFR at ≤3 months,
6 months (±3 months) and 1 year (±3 months). All
patients registered on the database had data collected in
routine clinical care, which was then retrospectively
accessed for analysis. The following anonymised data
were passed onto the research team: database ID, date
of registration, date of test results and results for: lithium
and creatinine, patient’s year of birth and gender.
The sample
Patients were included for analysis if they were registered
on the database between its inception in 2002 to the end
of January 2013 and had at least one lithium and creatin-
ine reading recorded. The lithium level ranges chosen to
be analysed were: all levels ≤0.8 mmol/L (reference
group) and one exposure to 0.81–1.0, 1.01–1.2 or 1.21–
2.0 mmol/L, as these ranges reﬂect current UK practice
and consensus agreement.1 12 The reference group was
made up of patients whose lithium levels never exceeded
0.8 mmol/L in the time they were registered on the data-
base. Lithium levels that remained in the same range for
the 3 months after the initial test were classed as the same
exposure, as this is the routine monitoring frequency
within the UK. The ﬁrst instance of a level within the
highest group recorded was classed as the point of expos-
ure and started the follow-up period. After all exposure
events, patients remained on lithium for the duration of
the follow-up period they were included in, be this
≤3 months, 6 months (±3 months) or 1 year (±3 months).
If lithium levels recorded during this follow-up period
again exceeded 0.8 mmol/L, eGFR levels up to the last
known lithium reading ≤0.8 mmol/L were used and after
that the patient was not included in the analysis. Levels
above 5.0 mmol/L were not included for analysis as these
were likely to have been erroneous levels.13 Patients who
had creatinine levels outside of the range 30–1500 µmol/
L were also excluded, as the simpliﬁed modiﬁcation of
diet in renal disease (MDRD) equation used was not vali-
dated for levels outside of this range.14 To determine the
start point for follow-up for patients in the reference
group, the median time patients in the exposure groups
were registered on the database before their exposure
event was added to the date of joining the database for
patients in the reference group to create a pseudo expos-
ure date. The follow-up periods of ≤3 and 6 months
(±3 months) are in line with the current UK guidance for
three monthly monitoring, allowing for leeway in the test
frequency due to using real-life data. The ﬁnal time point
for follow-up was taken as 1 year (±3 months) and this was
used as the time period reference group.
Statistical analysis
STATA SE V.12.1 was used for the analysis (StataCorp,
2011, Stata Statistical Software: Release 12. College Station,
Texas, USA: StataCorp LP). Lithium patients from the
database were classiﬁed according to exposure group,
and their gender and age at the time of the exposure
event was recorded and used to calculate eGFR. A
random effects repeated measures mixed model with an
interaction with time was run to establish if there was a
relationship between follow-up eGFR and the lithium
level exposure group, adjusting for baseline eGFR.
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RESULTS
In total, data for 2712 patients were extracted for the
research team. Following exclusions of patients who did
not have the required data recorded there were 699
patients left for inclusion in the analysis, with ages
ranging from 18 to 96 at the time of exposure. Figure 1
describes the process of sample selection.
Table 1 shows the basic demographics of the patients
who were included for analysis and demonstrates that
the balance of males and females and different ages at
exposure was maintained. There were only 16 patient
records with levels recorded 2.01–5.0 mmol/L, so no
further analysis was performed on this group as the
small sample size is associated with a lack of statistical
reliability.
The percentage change in mean eGFR from baseline
to ≤3 months, 6 months (±3 months) and 1 year
(±3 months) of follow-up is presented in table 2. The
major change in eGFR was in the ﬁrst 3 months follow-
ing the exposure. Table 3 shows the results from a
random effects repeated measures mixed model with an
interaction with time. The ≤0.8 mmol/L exposure
group and the 1 year (±3 months) time period were
used in this model as the reference groups. Using the
simpliﬁed MDRD equation, gender and age are taken
into consideration when calculating eGFR so no further
adjustments were required.
Being in exposure groups 3 or 4 leads to a signiﬁcant
decrease in eGFR at ≤3 months follow-up (interaction
p=0.047 and p=0.040, respectively) as detailed in table 3.
No other main effects or interactions were signiﬁcant,
suggesting that eGFR levels seem to recover over time.
DISCUSSION
The results from this analysis show for the ﬁrst time that
a single exposure to a lithium level >1.0 mmol/L is asso-
ciated with an increased risk of renal impairment in the
ﬁrst 3 months after exposure with a percentage change
of −3 and −5, respectively. However, by 6 months
Figure 1 Process of sample selection.
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(±3 months) there is no detectable difference from the
mean baseline eGFR. Further work is ongoing to fully
establish the extent of recovery of the kidneys from mul-
tiple exposures of these lithium levels. It has been
shown from a previous national audit in 2009 that only
30% of patients had lithium levels taken at a frequency
meeting current National Institute for Health and Care
Excellence guidelines for three monthly lithium levels.15
Even assuming that patients are monitored in line with
this guidance, patients could remain at these levels for
up to 4 months and it is not yet clear if the detrimental
effects on eGFR of each single exposure are additive.
These ﬁndings not only suggest that a single exposure to
a lithium level >1.01 has a signiﬁcant effect on eGFR in
the 3 months after exposure, but the higher the level
the greater the effect.
The population studied is relatively comparable to
other lithium taking populations in terms of age and
gender of patients. The mean age of our sample at the
time of exposure was 59, which is slightly higher than
the means seen in a national audit from 2009 and a
recent cohort study using data from 1990 to 2007 of 55
and 48.8, respectively.15 16 This is to be expected for our
sample as compared to the rest of the UK, as Norfolk
has a higher percentage of population over the age of
65.17 Given the worldwide aging population and their
associated increased sensitivity to adverse effects with
relatively low serum levels for multiple medicines includ-
ing lithium, the Norfolk data set presents an opportunity
to further examine lithium levels and their effect on
older adults (age >60).9 10
A recent retrospective cohort study conﬁrmed that any
exposure to lithium is associated with an increased risk
of renal failure. However, the role of duration of lithium
exposure and the variation of risk at different lithium
levels used in practice could not be conﬁrmed.16 By
comparing different ranges of lithium level exposures to
a reference group of lithium-treated patients whose
levels never exceeded 0.8 mmol/L, the variation of risk
from single exposures of the different lithium levels
used in practice could be determined.
There are several limitations to this analysis. First,
there is no untreated group studied, due to the retro-
spective nature of the study design, to compare the
decline in renal function seen over the follow-up
periods to those patients who were not exposed to
lithium at all. The eGFR was calculated for all patients
using the simpliﬁed MDRD equation. However, as race
was not recorded the calculated eGFR results could not
be corrected for any African-American patients. Owing
to the predominantly Caucasian population studied this
is not likely to have been a signiﬁcant factor.18 As eGFR
is affected by age, fractional age was used in the analysis
to minimise this impact. The results of the analysis are
not changed by analysing plasma creatinine instead of
eGFR. Diabetes mellitus, hypertension and cardiac
disease are prominent risk factors for renal glomerular
function in the general as well as lithium-treated popula-
tions, however, these data were not reliably available
from the database and could therefore not be included
in the analysis. Duration of lithium treatment has been
linked with a decline in renal function, however, the full
duration of lithium treatment before the analysis is not
known; it was only known that patients had been on
lithium for 1 year prior to analysis.9 19
This analysis focused on single exposures to various
lithium levels and the association with eGFR in ≤3 and
6 months (±3 months) post exposure. If the decline in
renal function is reﬂected in a longer follow-up period
with multiple exposure events it could have signiﬁcant
consequences for the routine monitoring of lithium and
the follow-up monitoring of patients who have ever had
lithium levels >1.0 mmol/L, whether or not they con-
tinue with lithium treatment. Determining if the number
of exposures the kidney has from different lithium levels
and the duration of these exposures or if it is the degree
of the lithium level that determines the impact on renal
function is clinically relevant for continued monitoring.
Currently this analysis suggests that even short-term
exposure to elevated lithium levels has a signiﬁcant
impact on glomerular renal function in the ﬁrst
3 months following exposure, and regular monitoring of
lithium levels and timely responses to these levels is crit-
ical.19 It is still not known whether the kidneys can fully
recover this lost function or if the effects of multiple
exposures are additive; as such we suggest that lithium
level monitoring should be undertaken at least every
3 months, in line with current UK guidelines, and not be
reduced further until the impact of more than one expos-
ure to these lithium levels has been fully established. A
small change in GFR of 5 mL/min in an individual
patient may well be due to variability in measurement of
plasma creatinine, and is unlikely to lead to any action,
unless it was sustained or there was further deterioration,
which is another reason for regular monitoring. The
results of this analysis and the on-going further work
Table 1 Baseline demographics (all figures are number, (%))
Gender Age
Exposure group n Female <20 20–29 30–39 40–49 50–59 >60
<0.8 mmol/L (group 1) 183 101 (55.2) 0 (0) 9 (4.9) 26 (14.2) 41 (22.4) 36 (19.7) 71 (38.8)
0.81–1.0 mmol/L (group 2) 407 251 (61.7) 0 (0) 16 (3.9) 34 (8.4) 62 (15.2) 79 (19.4) 216 (53.1)
1.01–1.2 mmol/L (group 3) 38 24 (63.2) 0 (0) 1 (2.6) 4 (10.5) 3 (7.9) 9 (23.7) 21 (55.3)
1.21–2.0 mmol/L (group 4) 55 31 (56.4) 1 (1.8) 2 (3.6) 3 (5.5) 9 (16.4) 12 (21.8) 28 (50.9)
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Table 2 Change in eGFR by exposure group and time period
Exposure
group
Baseline ≤3 months 6 months (±3 months) 12 months (±3 months)
Mean eGFR
(95% CI) n
Mean eGFR
(95% CI) n
Percentage change
from baseline
Mean eGFR
(95% CI) n
Percentage change
from baseline
Mean eGFR
(95% CI)
n
Percentage change
from baseline
≤0.8 mmol/L
(group 1)
70.7 (68.4 to 73.0)
183
69.8 (66.3 to 73.3)
111
−0.26 71.1 (68.5 to 73.8)
145
1.02 68.8 (65.5 to 72.1)
138
−0.20
0.81–1.0 mmol/L
(group 2)
70.6 (68.8 to 72.3)
407
69.6 (67.6 to 71.6)
368
−1.77 71.8 (69.4 to 74.2)
277
0.63 71.3 (68.2 to 74.3)
174
0.61
1.01–1.2 mmol/L
(group 3)
73.5 (67.9 to 79.1)
38
70.1 (64.1 to 76.1)
35
−3.88 78.4 (71.1 to 85.6)
22
3.88 71.4 (63.4 to 79.3)
13
8.24
1.21–2.0 mmol/L
(group 4)
72.1 (67.1 to 77.1)
55
66.7 (60.7 to 72.6)
51
−5.40 69.8 (61.8 to 77.8)
29
0.81 73.6 (64.2 to 83.1)
21
3.35
eGFR, estimated-glomerular filtration rate.
Table 3 Random effects repeated measures mixed model to predict eGFR, adjusting for baseline eGFR
Independent variable Coefficient (95% CI) p Value Coefficient (95% CI) p Value
Exposure Exposure×time interactions
0.81–1.0 mmol/L (group 2) 0.23 (−1.75 to 2.24) 0.814 Group 2×time 1 −1.16 (−3.42 to 1.10) 0.314
1.01–1.2 mmol/L (group 3) 2.78 (−2.11 to 7.68) 0.266 Group 2×time 2 −0.57 (−2.72 to 1.58) 0.603
1.21–2.0 mmol/L (group 4) 0.43 (−3.48 to 4.44) 0.834 Group 3×time 1 −5.18 (−10.3 to −0.08) 0.047
Time Group 3×time 2 −1.91 (−7.13 to 3.31) 0.473
≤3 months (time 1) −0.35 (−2.17 to 1.47) 0.705 Group 4×time 1 −4.45 (−8.70 to −0.19) 0.040
6 months (±3 months)(time 2) 0.83 (−0.82 to 2.50) 0.322 Group 4×time 2 −2.29 (−6.61 to 2.02) 0.298
eGFR, estimated-glomerular filtration rate.
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could impact on monitoring guidance for patients on
lithium, and even those who have ceased treatment, if
they have ever been exposed to a level that is shown to
have a negative impact on renal function.
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